EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
EMERYVILLE, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option The Regenerative Medicine Advanced Therapies ...
The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A patient with lupus nephritis who received KYV-101 ...
Just as you must repeatedly complete KYC to verify your bank account, similarly, completing KYC will now be mandatory to verify your vehicle's FASTag. All vehicle owners in the country will be ...
(MENAFN- GlobeNewsWire - Nasdaq) KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis ...